Mobilise-D-Facebook cover - 02

Connecting digital mobility assessment to clinical outcomes
for regulatory and clinical endorsement



Mobilise-D is a 5-year, IMI-funded project that will produce validated and accepted digital mobility outcomes to monitor daily life gait of people with different mobility problems, with the goal to improve follow-up and personalized care.



Mobilise-D will perform a technical and clinical validation of a sensor-algorithm pair in different patient groups. We maintain close dialogue with the European Medicines Agency (EMA) to facilitate the process of regulatory approval.



The Mobilise-D consortium consists of 34 partners from Europe and the USA. Over 150 professionals with technical, clinical, and regulatory expertise will work together to bring digital mobility outcomes to the clinic.                                                                  

Mobility – how well we walk – is an important marker of health; a slow walking speed is associated with greater mortality, morbidity, cognitive decline, dementia, and fall risk. As the population ages, the number of people experiencing mobility challenges is expected to rise. However, accurately assessing people’s mobility, especially in the real daily life world, is far from easy.

Mobilise-D will develop a comprehensive system to monitor and evaluate people’s gait based on digital technologies, including sensors worn on the body. The project focuses on conditions which often affect mobility, namely chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure.

The Mobilise-D results will help to improve the accurate assessment of daily life mobility in clinical trials and patient treatment, thereby contributing to improved and more personalised care.

Patient Groups

Mobilise-D will focus on five different patient groups that together represent respiratory problems (chronic obstructive pulmonary disease – COPD), neurodegenerative conditions (Parkinson’s disease – PD), neuroinflammatory problems (multiple sclerosis – MS), osteoporosis and sarcopenia (hip fracture recovery/proximal femoral fracture – PFF), and cardiac pathology (congestive heart failure – CHF).

These patient groups cover a range of walking speed, mobility challenges, and potential events that we care about, such as improving versus worsening of function, falls, hospitalisation, nursing home admission, and death. Furthermore, these patient groups will be followed at 12 different sites across Europe, ensuring a good geographical representation and covering a diverse representation of health care organisation, such as in- versus outpatient care, as well as public versus private health services.

Read More

Twitter Feed

#MobiliseD’s @Cameronjkirk presented preliminary findings on what real-world walking speed tell us about Parkinson's disease at the #NEPG2020. Well done Kirk! #wearables #PD @NEPGconference @EFPIA @IMI_JU
Mobilise_D photo
Cam Kirk @Cameronjkirk
First ever conference today! (shame it's virtual). My poster is titled 'What does real-world walking speed tell us about Parkinson's disease?' and it presents some preliminary findings from a publication I've been working on! #NEPG2020

Latest News

NIHR: Monitoring patients’ mobility continues despite new lockdown

Monitoring patients’ mobility during the COVID19 pandemic could easily have been impossible due to lockdown and restrictions such as social distancing. However, this isn’t the case for the Mobilise-D technical validation study (TVS) where 120 participants with chronic obstructive pulmonary disease, Parkinson’s disease, multiple sclerosis, congestive heart failure or hip fracture, along with healthy older adults, will be enrolled. Our test sites in Newcastle and Sheffield have found a way to work around the distancing restrictions to keep the study open, and confirmed that the technical validation…

Upcoming Events

No event found!